NEW YORK, NY / ACCESSWIRE / May 30, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Investors who purchased Integra securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/iart.
The investigation concerns whether Integra has violated federal securities laws.
On May 23, 2023, Integra issued a recall of all products manufactured in its Boston, Massachusetts facility that were distributed between March 1, 2018 and May 22, 2023. Specifically, Integra stated that it "identified through an internal investigation process in its Boston facility deviations with endotoxin testing that may have resulted in the release of products with higher levels of endotoxins than permitted by the product specifications. Higher levels of endotoxins can induce an immune response, leading to a post-operative fever." On this news, Integra's stock price fell $10.24 per share, or 20.19%, to close at $40.48 per share on May 23, 2023.
If you are aware of any facts relating to this investigation or purchasedIntegra shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/iart. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC